Cargando…

Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension

BACKGROUND: High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arte...

Descripción completa

Detalles Bibliográficos
Autores principales: Khirfan, Ghaleb, Tejwani, Vickram, Wang, Xiaofeng, Li, Manshi, DiDonato, Joseph, Dweik, Raed A., Smedira, Nicholas, Heresi, Gustavo A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973565/
https://www.ncbi.nlm.nih.gov/pubmed/29813091
http://dx.doi.org/10.1371/journal.pone.0197700
_version_ 1783326656368214016
author Khirfan, Ghaleb
Tejwani, Vickram
Wang, Xiaofeng
Li, Manshi
DiDonato, Joseph
Dweik, Raed A.
Smedira, Nicholas
Heresi, Gustavo A.
author_facet Khirfan, Ghaleb
Tejwani, Vickram
Wang, Xiaofeng
Li, Manshi
DiDonato, Joseph
Dweik, Raed A.
Smedira, Nicholas
Heresi, Gustavo A.
author_sort Khirfan, Ghaleb
collection PubMed
description BACKGROUND: High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). OBJECTIVES: We aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH. METHODS: We retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort. RESULTS: HDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34–57 mg/dl; PAH: 35.3, 29–39 mg/dl; Control: 49, 40–60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity. CONCLUSIONS: HDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH.
format Online
Article
Text
id pubmed-5973565
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-59735652018-06-08 Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension Khirfan, Ghaleb Tejwani, Vickram Wang, Xiaofeng Li, Manshi DiDonato, Joseph Dweik, Raed A. Smedira, Nicholas Heresi, Gustavo A. PLoS One Research Article BACKGROUND: High Density Lipoprotein Cholesterol (HDL-C) has various anti-inflammatory, anti-atherogenic, anti-oxidant and anti-coagulant properties that improve vascular function. The utility of HDL-C as a biomarker of severity and predictor of survival was described in patients with pulmonary arterial hypertension (PAH). No prior study has assessed the utility of HDL-C in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH). OBJECTIVES: We aim to measure HDL-C levels in CTEPH patients and compare it to those in PAH patients and controls and determine HDL-C associations with markers of disease severity, hemodynamics and mortality in CTEPH. METHODS: We retrospectively included patients with CTEPH, identified from the Cleveland Clinic Pulmonary Hypertension Registry. All patients had right heart catheterization (RHC) and imaging studies consistent with CTEPH. We collected demographics, co-morbidities, baseline laboratory data including plasma HDL-C, six-minute walk test (6MWT), echocardiography and RHC. HDL-C levels were compared to a cohort of patients with cardiovascular risk factors and a previously published PAH cohort. RESULTS: HDL-C levels were available for 90 patients with CTEPH (age: 57.4±13.9 years; female 40%), 69 patients with PAH (age: 46.7±12.8 years; female 90%) and 254 control subjects (age: 56.7±13 years; female 48%). HDL-C levels in CTEPH patients were lower compared to controls and higher compared to PAH patients (median, IQR: CTEPH: 44, 34–57 mg/dl; PAH: 35.3, 29–39 mg/dl; Control: 49, 40–60 mg/dl; p < 0.01 for both pairwise comparisons). In CTEPH, higher HDL-C was associated with decreased prevalence of right ventricular dilation on echocardiography (p = 0.02). 57 patients with CTEPH underwent pulmonary thromboendarterectomy, higher HDL-C was associated with a larger decrement in postoperative pulmonary vascular resistance (PVR) (r = 0.37, p = 0.049). HDL-C was not associated with mortality or other markers of disease severity. CONCLUSIONS: HDL-C levels in CTEPH patients were lower compared to control subjects, but higher compared to PAH patients. Higher HDL-C in CTEPH was associated with less right ventricular dilation and greater decrement in postoperative PVR. These data suggest that HDL-C may be a useful marker of small vessel disease in CTEPH. Public Library of Science 2018-05-29 /pmc/articles/PMC5973565/ /pubmed/29813091 http://dx.doi.org/10.1371/journal.pone.0197700 Text en © 2018 Khirfan et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Khirfan, Ghaleb
Tejwani, Vickram
Wang, Xiaofeng
Li, Manshi
DiDonato, Joseph
Dweik, Raed A.
Smedira, Nicholas
Heresi, Gustavo A.
Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title_full Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title_fullStr Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title_full_unstemmed Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title_short Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
title_sort plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973565/
https://www.ncbi.nlm.nih.gov/pubmed/29813091
http://dx.doi.org/10.1371/journal.pone.0197700
work_keys_str_mv AT khirfanghaleb plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT tejwanivickram plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT wangxiaofeng plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT limanshi plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT didonatojoseph plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT dweikraeda plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT smediranicholas plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension
AT heresigustavoa plasmalevelsofhighdensitylipoproteincholesterolandoutcomesinchronicthromboembolicpulmonaryhypertension